Posted on 11/01/2010 in Medical Company Product News Boston Scientific has revealed that the first participants have enrolled in its TAXUS Liberte Stent clinical trial.
The study will evaluate real-world clinical outcomes data for the TAXUS Liberte Paclitaxel-Eluting Coronary Stent System.
It will be examined in combination with a dual antiplatelet therapy drug regimen that includes the new antiplatelet treatment Effient and aspirin.
Eli Lilly and Daiichi Sankyo, which manufacturers Effient, are co-sponsors of the research.
The primary endpoint of the research is to reduce the rate of cardiac deaths or incidents of myocardial infarction after a period of 12 months.
Keith Dawkins, senior vice-president and associate chief medical officer at Boston Scientific, commented: "The TAXUS Liberte post-approval study will allow us to further assess the second-generation TAXUS Liberte Stent [...] in a variety of complex lesions."
In other Boston Scientific news, the firm appointed Nelda Connors to its board of directors last month - the current president of the electrical and metal products division of Tyco International.Other news stories from 11/01/2010
Read more in the Zenopa News Archive
How this news is generated
|
